Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients.

Continue

Do you trust this headline?

Based on recent headline ratings, 82% of this readership currently trusts the local media, which has an average score of 82% regionally and is currently trending positiveneutrally.

82%

Media Trust Score82%

Read All

In

News